Cingulate Inc. CING
4.31 USD -0.25 (-5.41%)
Nov 5, 2026, 12:11 PM EST
4.25 Day range 4.57
3.16 52-week range 11.89
- YTD
- -0.62%
- 1 year
- +12.91%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…
globenewswire.com Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma Chief Commercial Officer Bryan Downey Joins Panel Discussion on…
benzinga.com Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9 Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.
benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $52 to $44.
benzinga.com Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14)…
globenewswire.com Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to…
globenewswire.com Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision…
globenewswire.com Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology Publication helps establish the…
benzinga.com Cingulate Joins Russell 3000E Index Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of…
globenewswire.com Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility…
globenewswire.com Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform…
benzinga.com Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts ORCL PT, Needham raises APLD PT, Morgan Stanley raises AAPL PT, BTIG raises NRIX PT, GLJ Research…
benzinga.com Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $52 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $55 to $52.
newsfilecorp.com Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
reuters.com US FDA declines to approve Cingulate's ADHD drug Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder.
benzinga.com Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301.…
globenewswire.com Cingulate Receives Complete Response Letter from FDA for CTx-1301 No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is…- benzinga.com HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy and maintains $20 price target.
- benzinga.com Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.53) by 79.25 percent. This is a 10.38 percent increase over losses of $(1.06)…
globenewswire.com Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings page. Price targets and ratings altered for CING, WING, DEFT, FANG, PJT, DOCS, and AMZN.- benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $55 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $58 to $55.
newsfilecorp.com Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues…
benzinga.com Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14 Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $16 to $14.
benzinga.com What's Going On With Cingulate Stock Today? Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Cingulate Q4 EPS $(0.84) Misses $(0.61) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.61) by 37.03 percent. This is a 500 percent decrease over losses of $(0.14)…
invezz.com Why did Cingulate stock skyrocket today? Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
defenseworld.net Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, Marketbeat.com reports. One…
defenseworld.net Cingulate Inc. (NASDAQ:CING) Receives Consensus Recommendation of “Moderate Buy” from Analysts Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, Marketbeat reports.…- benzinga.com Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Executive Chairman Of The Board But Will Continue To Serve As Chairman Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed on August 14, 2025, the…
- benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $62 to $58.
- benzinga.com Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16 Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $17 to $16.
newsfilecorp.com Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results…- benzinga.com Cingulate Releases Phase 3 Trial Results For Its ADHD Treatment CTX-1301 Showing The Drug Met Its Primary Endpoints, Showing Dose-Dependent Improvements On ADHD Symptom And Severity Scales, And Demonstrated Effective Once-Daily Symptom Relief Using The Company's Precision Timed Release Technology Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
- benzinga.com Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual Meeting In Chicago Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
globenewswire.com Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to…
benzinga.com Roth Capital Maintains Buy on Cingulate, Raises Price Target to $17 Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $10 to $17.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Cingulate Announces That U.S. FDA Accepts For Review Its New Drug Application For CTx-1301, Its Lead ADHD Treatment Candidate For Children And Adults Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
- benzinga.com Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, Its Lead Drug Candidate For Treating ADHD Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation
globenewswire.com Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval- benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $62 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $61 to $62.
newsfilecorp.com Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25 Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate reported 2Q25 results…- benzinga.com Cingulate Q2 EPS $(1.09) Misses $(0.84) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.84) by 29.3 percent. This is a 80.07 percent increase over losses of $(5.47)…